AbbVie (ABBV) Stock Forecast & Price Target

AbbVie is positioned for strong growth, with management increasing its 2025 revenue guidance to approximately $59.7 billion and non-GAAP EPS expectations to a range of $12.09-$12.29, reflecting a positive upward revision of 10 cents at the midpoint. The company's performance for 1Q 2025 was robust, achieving sales of $13.34 billion, driven by significant contributions from its immunology and oncology franchises, particularly Skyrizi, Rinvoq, Imbruvica, and Venclexta. Additionally, the recent strategic acquisitions of Cerevel and ImmunoGen are expected to further enhance AbbVie's diversified portfolio and long-term growth outlook in the neuroscience and oncology segments.

AbbVie faces several significant challenges that contribute to a negative outlook for its stock, primarily revolving around disappointing commercial execution across key assets, particularly in immunology and aesthetics. The anticipated erosion of Humira's market share due to the launch of biosimilars, coupled with limited market penetration for Rinvoq and Skyrizi, raises concerns about achieving long-term revenue expectations. Additionally, macroeconomic headwinds and competitive pressures in both the aesthetics and oncology segments create uncertainty about AbbVie's future financial performance, particularly in light of pipeline risks and potential regulatory setbacks.